Cytotoxicity of chlorambucil immobilized on magnetic iron oxide nanoparticles Fe3O4
Micro & Nano Letters, 2021 Chlorambucil is a nitrogen mustard alkylating agent used for the treatment of various malignant and non‐malignant cancers. The use of the chemotherapeutic is limited by its toxic side effects which precludes the use of optimal doses.
Julia Nowak‐Jary +2 more
doaj +1 more source
The curative effect of Cymbopogon citrates volatile oil against chlorambucil drug toxicity [PDF]
Journal of Bioscience and Applied Research, 2019 Chlorambucil (CLB) is a bifunctional alkylating drug widely used as an anticancer agent and immunosuppressant. CLB mutagenicity, teratogenicity, and carcinogenicity are indicated based on their structure and clinical history.
Zakaria Teleb +6 more
doaj +1 more source
The Possible Ameliorative Action of L-Carnitine Against Chlorambucil-Induced Testicular Damage in Adult Rat: Histological Study [PDF]
The Egyptian Journal of HistologyIntroduction: The safety of anti-cancer agents on normal tissues has come under examination due to the increase in the usage of these medications. Chlorambucil, which is anticancerous drug is associated with toxic side effects on testes.
Diana Aziz +3 more
doaj +1 more source
The Potential Protective Effect of L-Ascorbic Acid against Chlorambucil Induced Hepatorenal Toxicity in Adults Male Albino Rats [PDF]
Ain Shams Journal of Forensic Medicine and Clinical Toxicology, 2016 The high incidence of neoplastic diseases have led to manifacturing of many antineoplastic drugs to combat these diseases. Treatment with chloambucil in high dose is associated with toxicities to many organs.
Ghada Hamam, Marwa Fawzi, Rabab Hafiz
doaj +1 more source
Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
EMBO Molecular Medicine, 2019 Due to compromised homologous recombination (HR) repair, BRCA1‐ and BRCA2‐mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression.
Eliana MC Tacconi +23 more
doaj +1 more source
Veterinární Medicína, 2008 Chronic lymphatic leukemia (CLL), incurable by standard treatments, may be potentially cured by allogeneic hematopoietic stem cell transplantation. Since CLL affects predominantly older people, there is a need for some low-toxicity conditioning with, on ...
J. Tomenendalova +5 more
doaj +1 more source
Chlorambucil effect on B lymphocites in the peripheral blood of patients with chronic lymphocytic leukemia: Cell ultrastructure investigation [PDF]
Vojnosanitetski Pregled, 2003 B type Chronic Lymphocytic Leukemia (B-CLL) is a malignant disease characterized by the progressive accumulation of morphologically mature, but immunologically dysphunctional CD 5+ lymphocytes in the blood, bone marrow and lymphatic organs in the early ...
Brajušković Goran R. +2 more
doaj +1 more source
Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
Frontiers in Pharmacology, 2023 Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated ...
Hongyu Qin +5 more
doaj +1 more source
Kolaviron and L-Ascorbic Acid Attenuate Chlorambucil-Induced Testicular Oxidative Stress in Rats
Journal of Toxicology, 2014 Chlorambucil (4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid) is an alkylating agent, indicated in chronic lymphocytic leukaemia. Kolaviron (KV), a biflavonoid complex from Garcinia kola, and L-ascorbic acid (AA) are known to protect against ...
Ebenezer Tunde Olayinka, Ayokanmi Ore
doaj +1 more source
Chlorambucil-Bearing Hybrid Molecules in the Development of Potential Anticancer Agents
Molecules, 2023 Increasing cases of cancer have been a primary concern in recent decades. Developing new chemotherapeutics is challenging and has been faced with limitations, such as multidrug resistance, poor specificity, selectivity, and toxicity.
Sijongesonke Peter +1 more
doaj +1 more source